Home › Companies › NEUROCRINE BIOSCIENCES INC. › 2023-2024
Compiled from SEC Form N-PX filings and NEUROCRINE BIOSCIENCES INC.’s Form 8-K, filed 2024-05-23 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore NEUROCRINE BIOSCIENCES INC. in the interactive database Compare manager voting policies
These tallies are NEUROCRINE BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-23 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: William H. Rastetter, Ph.D. | 72,381,261 | -- | -- | 13,283,948 | 4,500,898 | Majority: yes |
| Elect Director: George J. Morrow | 80,403,845 | -- | -- | 5,261,364 | 4,500,898 | Majority: yes |
| Elect Director: Leslie V. Norwalk | 76,902,461 | -- | -- | 8,762,748 | 4,500,898 | Majority: yes |
| Elect Director: Christine A. Poon | 80,898,676 | -- | -- | 4,766,533 | 4,500,898 | Majority: yes |
| The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2020 Plan. | 76,076,416 | 9,499,523 | 89,270 | -- | 4,500,898 | Majority: yes |
| The Amended 2020 Plan was approved. • Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. | 84,641,389 | 5,451,051 | 73,667 | -- | -- | Passed |
Source: NEUROCRINE BIOSCIENCES INC., Form 8-K, filed with the SEC on 2024-05-23 — read the filing on EDGAR.
Each item below shows how the 564 asset managers that disclosed a NEUROCRINE BIOSCIENCES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NEUROCRINE BIOSCIENCES INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 16 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2020 Plan.”): 76,076,416 for, 9,499,523 against, per its Form 8-K filed 2024-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 76% for, 9% against (85% of the company cast a for/against vote).
The 557 asset managers below cast 97% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,720,636 | 518 | 0 | 0 | For |
| Vanguard | 10,560,083 | 0 | 0 | 0 | For |
| State Street | 4,821,195 | 0 | 0 | 0 | For |
| JPMorgan | 3,380,014 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,933,595 | 218,461 | 0 | 0 | For |
| Man Group plc | 2,268,940 | 0 | 0 | 0 | For |
| Dodge & Cox | 2,092,631 | 0 | 0 | 0 | For |
| Fidelity | 2,030,672 | 0 | 0 | 0 | For |
| Invesco | 1,809,565 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,675,222 | 0 | 0 | 0 | For |
| Charles Schwab | 1,462,265 | 0 | 0 | 0 | For |
| Renaissance | 1,450,218 | 0 | 0 | 0 | For |
| Janus Henderson | 1,391,296 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,055,000 | 0 | 0 | 0 | For |
| DSM CAPITAL PARTNERS LLC | 1,007,585 | 0 | 0 | 0 | For |
| Eaton Vance | 993,369 | 0 | 0 | 0 | For |
| Wellington | 959,016 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 923,979 | 0 | 0 | 0 | For |
| BROWN ADVISORY INC | 923,751 | 0 | 0 | 0 | For |
| Northern Trust | 896,224 | 1,976 | 0 | 0 | For |
| Point72 | 868,582 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 826,029 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 805,556 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 781,541 | 0 | 0 | 0 | For |
Showing the 25 largest of 557 asset managers. See all 557 in the interactive database.
Combines 6 wordings of this item as funds reported it.
94% Passed · of votes cast
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The Amended 2020 Plan was approved. • Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 84,641,389 for, 5,451,051 against — passed, per its Form 8-K filed 2024-05-23 (Item 5.07). Of all 100,600,000 outstanding shares: 84% for, 5% against (90% of the company cast a for/against vote).
The 142 asset managers below cast 99.6% of the shares they voted on this item FOR (36,594,229 for, 113,581 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,219 | 0 | 0 | 0 | For |
| State Street | 1,206,065 | 167 | 0 | 0 | For |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 508,568 | 0 | 0 | 0 | For |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 347,792 | 0 | 0 | 0 | For |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 305,967 | 0 | 0 | 0 | For |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 277,524 | 0 | 0 | 0 | For |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 214,044 | 0 | 0 | 0 | For |
Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.
Combines 7 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Christine A. Poon”): 80,898,676 for, 4,766,533 withheld, per its Form 8-K filed 2024-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 80% for, 5% withheld (85% of the company cast a for/withheld vote).
The 139 asset managers below cast 100% of the shares they voted on this item FOR (35,426,486 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,219 | 0 | 0 | 0 | For |
| State Street | 2,261 | 0 | 1,203,971 | 0 | Abstain |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 508,568 | 0 | 0 | 0 | For |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 347,792 | 0 | 0 | 0 | For |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 305,967 | 0 | 0 | 0 | For |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 277,524 | 0 | 0 | 0 | For |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 214,044 | 0 | 0 | 0 | For |
Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.
Combines 7 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: George J. Morrow”): 80,403,845 for, 5,261,364 withheld, per its Form 8-K filed 2024-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 80% for, 5% withheld (85% of the company cast a for/withheld vote).
The 139 asset managers below cast 100% of the shares they voted on this item FOR (34,874,437 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 76,767 | 0 | 1,272,452 | 0 | Abstain |
| State Street | 1,206,232 | 0 | 0 | 0 | For |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 508,568 | 0 | 0 | 0 | For |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 327,859 | 0 | 19,933 | 0 | For |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 54,858 | 0 | 251,109 | 0 | Abstain |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 249,326 | 0 | 28,198 | 0 | For |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 214,044 | 0 | 0 | 0 | For |
Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.
Combines 7 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Leslie V. Norwalk”): 76,902,461 for, 8,762,748 withheld, per its Form 8-K filed 2024-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 76% for, 9% withheld (85% of the company cast a for/withheld vote).
The 139 asset managers below cast 100% of the shares they voted on this item FOR (33,282,901 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 76,767 | 0 | 1,272,452 | 0 | Abstain |
| State Street | 1,206,232 | 0 | 0 | 0 | For |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 871,521 | 0 | Abstain |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 508,568 | 0 | 0 | 0 | For |
| Jackson National | 224,473 | 0 | 209,495 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 327,859 | 0 | 19,933 | 0 | For |
| TIAA | 0 | 0 | 340,311 | 0 | Abstain |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 54,858 | 0 | 251,109 | 0 | Abstain |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 249,326 | 0 | 28,198 | 0 | For |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 214,044 | 0 | 0 | 0 | For |
Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.
Combines 8 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: William H. Rastetter, Ph.D.”): 72,381,261 for, 13,283,948 withheld, per its Form 8-K filed 2024-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 72% for, 13% withheld (85% of the company cast a for/withheld vote).
The 139 asset managers below cast 100% of the shares they voted on this item FOR (32,792,406 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 76,767 | 0 | 1,272,452 | 0 | Abstain |
| State Street | 2,094 | 0 | 1,204,138 | 0 | Abstain |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 0 | 0 | 508,568 | 0 | Abstain |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 327,859 | 0 | 19,933 | 0 | For |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 305,967 | 0 | 0 | 0 | For |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 115,879 | 0 | 161,645 | 0 | Abstain |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 214,044 | 0 | 0 | 0 | For |
Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.
Combines 3 wordings of this item as funds reported it.
95% fund support · no official result
The 122 asset managers below cast 95% of the shares they voted on this item FOR (32,248,109 for, 1,813,928 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,138,627 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,576,285 | 228,991 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,219 | 0 | 0 | 0 | For |
| State Street | 2,094 | 1,204,138 | 0 | 0 | Against |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 305,967 | 0 | 0 | 0 | For |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 277,524 | 0 | 0 | 0 | For |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 214,044 | 0 | 0 | 0 | For |
| Lincoln Financial | 148,552 | 34,954 | 0 | 0 | For |
| Equitable | 175,187 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 172,563 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Combines 5 wordings of this item as funds reported it.
89% fund support · no official result
The 27 asset managers below cast 89% of the shares they voted on this item FOR (2,282,147 for, 278,356 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| Hartford | 508,568 | 0 | 0 | 0 | For |
| Prudential/PGIM | 54,290 | 223,023 | 0 | 0 | Against |
| Vanguard | 272,950 | 0 | 0 | 0 | For |
| SEI | 168,119 | 0 | 0 | 0 | For |
| Mercer Funds | 73,649 | 39,043 | 0 | 0 | For |
| Neuberger Berman | 105,161 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 89,159 | 0 | 0 | 0 | For |
| Northwestern Mutual | 75,500 | 0 | 0 | 0 | For |
| Russell Investments | 58,412 | 0 | 0 | 0 | For |
| Federated Hermes | 52,945 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 50,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,931 | 0 | 48,051 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 19,621 | 0 | 0 | 0 | For |
| Putnam | 0 | 13,852 | 0 | 0 | Against |
| TIMOTHY PLAN | 8,587 | 0 | 0 | 0 | For |
| THOMPSON IM FUNDS INC | 7,625 | 0 | 0 | 0 | For |
| TEALWOOD ASSET MANAGEMENT INC | 7,574 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 0 | 0 | 0 | 0 | Unknown |
| MassMutual | 6,460 | 0 | 0 | 0 | For |
| Global X | 3,858 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 1,921 | 0 | 0 | Against |
| NEW COVENANT FUNDS | 717 | 0 | 0 | 0 | For |
| Adviser Managed Trust | 524 | 0 | 0 | 0 | For |
| SYNTAX ETF TRUST | 0 | 517 | 0 | 0 | Against |
Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.
99.2% fund support · no official result
The 7 asset managers below cast 99.2% of the shares they voted on this item FOR (79,715 for, 602 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Empower | 46,263 | 0 | 0 | 0 | For |
| Lincoln Financial | 23,200 | 0 | 0 | 0 | For |
| TIMOTHY PLAN | 8,587 | 0 | 0 | 0 | For |
| Symmetry Panoramic Trust | 250 | 0 | 1,614 | 0 | Abstain |
| iA Global Asset Management Inc. | 1,410 | 0 | 0 | 0 | For |
| Regime de rentes du Mouvement Desjardins | 0 | 602 | 0 | 0 | Against |
| Warren Street Wealth Advisors, LLC | 5 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% fund support · no official result
The 4 asset managers below cast 100% of the shares they voted on this item FOR (47,084 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TEALWOOD ASSET MANAGEMENT INC | 30,296 | 0 | 0 | 0 | For |
| TIMOTHY PLAN | 8,587 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 7,684 | 0 | 0 | 0 | For |
| SYNTAX ETF TRUST | 517 | 0 | 0 | 0 | For |
Ranked by the number of NEUROCRINE BIOSCIENCES INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 100,600,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 12.65% |
| 2 | Vanguard | 10.50% |
| 3 | State Street | 4.79% |
| 4 | JPMorgan | 3.36% |
| 5 | T. Rowe Price | 3.13% |
| 6 | Man Group plc | 2.26% |
| 7 | Dodge & Cox | 2.08% |
| 8 | Fidelity | 2.02% |
| 9 | Invesco | 1.80% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.67% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 12.63% | 13F |
| Vanguard Group | 9.65% | 13F |
| JPMorgan Chase | 4.70% | 13F |
| State Street | 3.97% | 13F |
| Renaissance Technologies | 2.24% | 13F |
| Morgan Stanley | 1.82% | 13F |
| T. Rowe Price | 1.81% | 13F |
| Geode Capital | 1.70% | 13F |
| Kevin C. Gorman, Ph.D. | 1.57% | DEF14A |
| Invesco | 1.13% | 13F |
Percentages above are of 100,600,000 shares outstanding, as reported by NEUROCRINE BIOSCIENCES INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEUROCRINE BIOSCIENCES INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At NEUROCRINE BIOSCIENCES INC.'s shareholder meeting held 2024-05-22, in the 2023-2024 proxy season, 564 asset managers reported how they voted in their SEC Form N-PX filings, covering 5,275 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory vote on the compensation paid to the Company's named executive officers; — FOR was 89% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: NEUROCRINE BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-05-23.
NEUROCRINE BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.